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Immune response in patients with cancer pain
Abstract
The role of perioperative pain management techniques on immune func-
tions in patients with malignancies is still poorly understood. Although the
suppression of cellular and humoral immune response in carcinoma patients
is a subject of great scientific interest, we know very little about the changes in
innate immunity (natural killer T cells-NKT cells, regulatory T cells-Tregs)
following tumor growth, as well as in acquired immunity and cytotoxic
functions of NK cells in these patients undergoing surgery and the involve-
ment of different perioperative analgesia techniques. Immune compromise
could affect the healing processes, postoperative infections and rate and size of
tumor metastases disseminated during operation and may be associated with
increased risk of mortality Immunosuppression is also a result of perioperative
psychological and physiological stress induced by the mechanisms closely re-
lated to hypothalamus-pituitary-adrenocortical axis, sympathetic nervous
system, cytokines, opioids and T cell signal molecule. Furthermore, peripheral
and central immune reaction play a key role in hyperalgesia and allodynia, as
a consequence of releasing proinflammatory cytokines (PIC) from activated
microglia and astrocytes. Release of PIC causes the augmented secretion of ex-
citatory neurotransmitters from synaptic nerves of primary afferent neuron,
representing PIC as very important mediators of enhanced pain in the periph-
ery and in the central nervous system. These findings emphasise that periope-
rative pain management in patients with malignancies is significant to atten-
uate developed serious immune suppression mediated by the complicated
network of neuro-immuno-endocrine interactions caused by the primary dis-
ease accompanied with exogenous and endogenous stimuli.
INTRODUCTION
Perioperative pain management is one of the most important diffi-culties that confront surgical patients. Inappropriate pain control
may result in a higher incidence of chronic postoperative pain with pro-
longed hospitalization, augmented postsurgical morbidity and mortal-
ity, health care costs, as well as unnecessary suffering of patients (1).
Cancer patients represent some of the most sensitive patients for pain
control, regarding surgical stress with accompanied suppression of
humoral and cellular immunity and diminished number and function
of T lymphocytes and natural killer (NK) cells (2). Immunosupression
during the perioperative period may be the consequences of opioids
and other anaesthetic agents, surgery, blood transfusion, pain, psycho-
logical stress and temperature changes, as well as the enhancement of
tumor metastasis in experimental conditions (3), which suggests that
adequate treatment of surgically mediated stress may even help to de-
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Overview
against the metastatic diffusion after cancer surgery (4).
Pain can induce neural circuits in the brain and activate
brain-controlled pathways to the periphery mediated by
hypothalamo-pituitary-adrenal axis and sympathetic ner-
vous system. Neurotransmitters and hormones from
these pathways bind receptors which are expressed by
immune cells and organs and therefore have the ability to
regulate immune response. Overproduction of cortisol
additionally leads to cellular immunosuppression (5).
Today, the involvement of glia cells incausing pain is
marked and drugs which have the possibility of activat-
ing glia cells represent powerful mechanisms to induce
pain (6).
The role of perioperative pain
management techniques on innate and
acquired immune response in patients
with cancer pain
The immune system distinguishes between multifac-
tor stimuli that allow reaction or rejection to the immu-
nological response. Natural killer (NK) and NK T (NKT)
cells are important in innate immune defense. Generally,
the appearance of such cells was associated with antitu-
mor and allergic immune response, chronic inflammatory
conditions, viral infections and autoimmune diseases.
These cells have the unique capacity to rapidly produce
large amounts of both T helper: Th1 and Th2 cytokines
(7–10). Regulatory T (Treg) cells have active suppression
mode and may induce peripheral tolerance (11).
Many cancer-related symptoms (pain, sleep distur-
bance, fatigue, cognitive dysfunction, etc) are connected
with the release of proinflammatory cytokines. These
cytokines: interleukin-1 (IL-1), interleukin-6 (IL-6) and
tumor necrosis factor-alpha (TNF-a) are released as a
part of immune response and may cause a syndrome
called sickness behavior which includes depression, leth-
argy, anorexia, fever, energy conservation, hyperalgesia,
etc. (12, 13). It is proposed that cancer-related symptom
and the cytokine-induced sickness behavior that develop
in animals after the administration of infections or inflam-
matory agents or proinflammatory cytokines share com-
mon cytokine-based neuroimmunologic mechanisms.
Cytokines are able to induce signaling that activates glial
cells. This interaction is part of an immune network of
injury and host that can lead to the development or facil-
itation of cytokine-related symptoms and pain / depres-
sion (14).
During perioperative pain management opioids has
shown their immunosuppressive effects. Acute, as well as
chronic administration of opioids decreases lymphopro-
liferation, natural killer (NK) activity, macrophage func-
tions, and the production of interferon-gamma (IFN-g)
and interleukin-2 (IL-2) in experimental animals (15).
Opioid administration has been associated with increas-
ed susceptibility of animals to bacterial and viral infec-
tions, and with decreased survival in tumor-bearing ani-
mals. Similar effects have been shown in humans, where
data suggest that opioids may have an adverse impact on
the immune system (16).
Recently many papers advocate regional anesthesia tech-
niques instead of general anesthesia in carcinoma patients
elected for surgery. Regional anesthesia is usually achieved
with a combination of local anesthetics and opioids, so the
total amount of opioids is reduced regarding general anes-
thesia as well as their adverse effects on the immune sys-
tem. Local anesthetics also show anti-inflammatory prop-
erties that contribute to better pain control (17). Hong JY
and Lim KT 2008 (18) showed that pre-emptive epidural
analgesia can affect the perioperative immune responses
and influence cancer management. Moreover, this analge-
sia technique is a good method of potentially controlling
perioperative immune response and preventing postoper-
ative pain in carcinoma patients.
Aristomenis et al. 2008 (19) in a retrospective study
suggests that paravertebral anesthesia and analgesia for
breast cancer surgery reduces the risk of recurrence or
metastasis during the initial years of follow-up. Biki et al.
2008 (20) compared anesthesia techniques for radical
prostatectomy and indicate that the epidural plus general
anesthesia group had an estimated 57% (95% confidence
interval ), 17–78% lower risk of cancer recurrence com-
pared with the general anesthesia plus opioids group,
with a corresponding hazard ratio of 0.43 (95% confi-
dence interval).
If we compare the effects on immune responses of
morphine and of the atypical opioid analgesic, tramadol,
given for postoperative pain, some interesting findings
exist. Tramadol and morphine showed similar analgesic
function, although tramadol induced an improvement of
postoperative immunosuppression and may be preferred to
morphine for the treatment of postoperative pain. Mor-
phine and tramadol share the common opioid mecha-
nism of function, but the affinity of tramadol for m-opioid
receptors is lower than that of morphine. On the other
hand the antinociceptive effects of tramadol are medi-
ated via a separate, nonopioid mechanism, mediated by
the inhibition of neuronal uptake of noradrenaline and
serotonin. Maybe these differences are the reason for the
diverse pharmacodynamic profile of morphine and tra-
madol on immune functions (21, 22).
CONCLUSION
Innate and acquired immune responses play a key role
in host defense. Patients with malignant diseases have di-
minished immune functions that can be modulated by
surgical stress, pain, tissue injury and invasive micro-or-
ganisms which can lead to augmented susceptibility to
postoperative infections and therefore difficulties in post-
operative recovery. A good choice of perioperative pain
management techniques plays an important role in the
immune response of patients with malignancies. Prospec-
tive trials evaluating the effects of regional analgesia and
opioid sparing on cancer recurrence seem warranted.
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